Aravind Palraj/LinkedIn
Jul 7, 2026, 22:23
Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“Antiphospholipid Syndrome is not just ‘start warfarin and follow INR.’
Management depends on:
- Thrombosis type (arterial vs venous)
- Obstetric profile
- Antibody pattern (triple-positive risk)
- Recurrent events
Triple-positive APS – Avoid DOACs Recurrent arterial events – Consider higher INR target Catastrophic APS – Anticoagulation plus steroids plus PLEX plus IVIG APS care is risk-stratified medicine.”
Find more posts featuring Aravind Palraj on Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026